|Bid||3.5600 x 2200|
|Ask||3.5900 x 1000|
|Day's Range||3.5100 - 3.7100|
|52 Week Range||3.2000 - 14.5400|
|Beta (3Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long...
Alpine gets $2 million from Adaptimmune now, and up to $290 million if the partnership is successful in producing next-generation cancer immunotherapies.
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.
If you're interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! James Noble became the CEO of AdaptimmuneRead More...
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
The big shareholder groups in Adaptimmune Therapeutics plc (NASDAQ:ADAP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Adaptimmune Therapeutics plc (NASDAQ:ADAP) as an investment opportunity by projecting itsRead More...